Evidence Development in Cancer Treatment - Real World: PREDiCTrw
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Overall survival
研究概览
简要总结
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with therapy that has preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost effectiveness in subjects with cancer. The goal of this study is to collect real world evidence with respect to quality of life and outcomes to support decision making.
详细描述
Clinical practice involves incorporating new data into treatment recommendations including non randomized phase I/II studies. Clinicians' decision-making is swayed by alternative endpoints like response rate (RR), depth of response and progression free survival (PFS), presumed to be surrogates for overall survival (OS). Determination of the added value of these new therapies in terms of outcomes and quality of life (QOL) is challenging in the absence of comparators in trials resulting in increased uncertainty in terms of outcomes, quality of life and cost-effectiveness.
With the possibility of a randomized clinical trial evidence being low in certain populations, the use of real world data (RWD) can provide information regarding therapies with preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost effectiveness. With RWD, patients may receive access to therapies and participate in the evidence generation package.
This study proposes to use RWD to generate evidence to evaluate therapies with preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost effectiveness. The key components include regular interval disease assessments (eg radiographic imaging) and collection of patient reported outcomes (PROs) using standardized QOL questionnaires. The aim is to provide high quality real world evidence (RWE) for assessment and economic modelling to reduce uncertainty and facilitate decision-making.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with cancer for which there remains ongoing questions regarding clinical effectiveness and/or cost effectiveness regarding a therapeutic agent
- •Eastern Co-operative Group (ECOG) 0-2
- •Life expectancy of at least 12 weeks
- •Adequate hematologic and end organ function for drug treatment per the clinician's assessment
- •Asymptomatic or treated brain metastases permitted
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% per year during the treatment period and for at least 5 months after the last dose.
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse with a female partner of childbearing potential or who is pregnant) or use contraceptive measures, and agreement to refrain from donating sperm, during the treatment period and for at least 5 months after the last dose.
- •Ability to give informed consent for the study procedures defined in this protocol.
排除标准
- •Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment.
- •Inability to complete quality of life questionnaires
- •Pregnancy or breastfeeding.
- •Any significant cardiovascular disease, comorbidity (i.e. recent major infection, HIV, tuberculosis) or major surgical procedure within 21 days that in the opinion of the investigator renders the proposed treatment unsafe.
- •Subjects who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.
结局指标
主要结局
Overall survival
时间窗: From date of initiation until the date of death from any cause, whichever came first, assessed up to 100 months
Overall survival from initiation of therapy
次要结局
- Response rate(From date of initiation until the date of death from any cause, whichever came first, assessed up to 100 months)
- Progression/event free survival(From date of initiation until the date of progression or date of death from any cause, whichever came first, assessed up to 100 months)
- Quality of life assessments(From date of initiation until the date of death from any cause, whichever came first, assessed up to 100 months)
- Quality adjust survival(From date of initiation until the date of death from any cause, whichever came first, assessed up to 100 months)
- Physician assessed response rate(From date of initiation until the date of death from any cause, whichever came first, assessed up to 100 months)